Needham Reiterates Buy on Vir Biotechnology, Maintains $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Vir Biotechnology (NASDAQ:VIR) and maintained a price target of $22.
August 04, 2023 | 3:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Vir Biotechnology and maintained a price target of $22.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $22 price target could potentially boost investor confidence in Vir Biotechnology, leading to a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100